Early proactive therapeutic drug monitoring with ustekinumab therapy in pediatric Crohn's disease: data from the prospective Canadian children IBD network.
The aim is to evaluate the impact of ustekinumab dosing on therapeutic outcomes in children with Crohn's disease.
Analyzed ustekinumab dosing in children with Crohn's disease from the Canadian children IBD network.
Compared drug levels between children under and over 40 kg at week 8.
Assessed the correlation between week 8 drug levels and later treatment outcomes.
Children under 40 kg required a higher dose of ustekinumab to achieve similar drug levels compared to those 40 kg and above.
Higher week 8 ustekinumab levels were linked to better treatment outcomes later on.
Abstract
Children 2) to achieve similar week 8 levels as children ≥40kg receiving conventional adult 6 mg/kg weight-tiered induction. Higher week 8 levels were associated with favorable later outcomes.